Injective ETF INJC on Nasdaq: Staking, Fees and Risks

The Canary Staked INJ ETF holds INJ, the native token of the Injective blockchain, and seeks to earn more INJ by staking it. Its shares began trading on Nasdaq on November 5, 2026 under the ticker INJC, so investors can get that exposure through a brokerage account instead of holding tokens in a wallet.

The fund is a Delaware statutory trust offered under the Securities Act of 1933. Its prospectus says it is not registered under the Investment Company Act of 1940 and is not subject to regulation under that law. BitGo Bank & Trust holds the trust's INJ, and U.S. Bank is the cash custodian.

Reports at launch listed two other proposed INJ funds, from 21Shares and REX-Osprey, which makes INJC the first of the three to reach the market. Staking itself is not new to US crypto funds. Spot Ethereum ETFs launched without it in 2024, but REX-Osprey brought a Solana staking fund to market in July 2025, and Grayscale enabled staking on its Ethereum products that October. INJC applies the same idea to a much smaller token.

The sponsor expects to stake at least 90% of the trust's INJ under normal circumstances. It can hold back more to meet redemptions, pay expenses or otherwise protect the trust. Accrued rewards are included in the trust's daily net asset value (NAV), and the trust may restake them, use them for expenses, or transfer or sell them to meet redemptions.

Two layers of cost sit between the network's reward rate and the shareholder. Staking fees are capped at 30% of rewards and are expected to be 30%. The sponsor also charges 1.10% a year on the trust's INJ, which it may choose to waive. As simple arithmetic, if exactly 90% of the INJ is staked and staking fees are 30%, the fund keeps about 63% of the gross staking rate. On those assumptions, the gross rate has to be above roughly 1.75% just to cover the sponsor fee, before any other expenses.

Launch coverage tends to focus on staking rewards. The prospectus spends just as much time on the ways those rewards can fall short, and four points stand out for anyone reading past the headline.

Injective is a Layer-1 blockchain aimed at financial applications. It offers an on-chain order book and, according to the project, was the first blockchain to build frequent batch auctions into the chain itself. Orders in a batch are revealed together and filled at one clearing price, a design intended to make front-running harder.

Injective reported average block times of about 0.65 seconds in 2024 and describes its Tendermint-based consensus as giving instant finality. These are the project's own figures. Batch auctions also apply to order matching, so they say little about an ordinary token transfer.

An ETF does not change that design. INJC buys INJ and stakes most of it, which adds to the tokens securing the network. Staked tokens are not sitting on an order book, so the listing should not be read as a direct increase in trading liquidity on Injective.

In the short term, very little. INJC is an investment product bought through a broker. A customer who buys it is not paying anyone in INJ, and the listing does not make a volatile token any more practical to accept at checkout.

A business deciding whether to accept crypto should start with what its customers already hold and are willing to spend. That usually points to dollar or euro stablecoins. Taria Pay supports USDC and USDT on Arbitrum and BNB Chain, and USDC and EURC on Base. It does not support INJ or the Injective network today. If you are weighing stablecoin payments for your business, these questions are a better starting point than any token's ETF news.

This article is general information based on Canary's prospectus dated November 4, 2026 and on reporting at launch. It is not investment, tax or legal advice.